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Abstract: 
Background Selenium was thought to play a role in cardiovascular disease (CVD) due to its 
antioxidant properties; however, evidence from observational studies and randomized 
controlled trials (RCT) has been inconsistent and controversial. We thus conducted a meta-
analysis to assess the discrepancies between observational and randomized trial evidence. 
Method We searched MEDLINE and EMBASE for eligible prospective studies regarding the 
relationship between selenium and CVD up to December 15, 2013 and finally included 16 
prospective observational studies and 16 RCTs. Random effects model was used to estimate 
the pooled relative risk (RR). Generalized least-squares trend test and restricted cubic spline 
model was performed to assess a linear and non-linear dose-response relation.  
Results Our meta-analysis of prospective studies showed a non-linear relation of CVD risk 
with blood selenium concentrations across a range of 30-165μg/L and a significant benefit of 
CVD within a narrow selenium range of 55-145μg/L. Our meta-analyses of RCTs showed 
that oral selenium supplements (median dose: 200μg/day) for 2 weeks to 144 months 
significantly raised blood selenium concentrations by 56.4μg/L (95% CI: 40.9, 72.0μg/L), 
whereas oral selenium supplements (median: 100μg/day) for 6 to 114 months caused no 
effect on CVD (RR=0.91; 95% CI: 0.74, 1.10).   
Conclusion Our meta-analysis in prospective studies demonstrated a non-linear inverse 
association between selenium status and CVD risk within a narrow selenium range, whose 
upper bound was over-elevated by raised selenium after supplementation and a null effect 
was observed in RCTs. These findings indicate the importance of considering selenium status, 
dose and safety in future trials.  
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Introduction 
Selenium exerts its biological functions on redox signaling, antioxidant defense, 
immune response, and thyroid hormone function mainly via selenium-dependent glutathione 
peroxidases (GPx) and other selenoproteins 1-4. Adequate intake of selenium may be 
beneficial for cardiovascular disease (CVDs), cancer, and other chronic diseases 5, 6. Food is 
the primary source of selenium contents in the human body; however, dietary selenium intake 
varies widely and primarily depends on the soil on which crops and fodder are grown 7. 
Selenium was added to various dietary supplements as a popular supplement 5, although the 
prevention effects on CVD have not been confirmed.  
There is a longstanding interest in the CVD research community regarding the potential 
yet unproven benefits or risks of selenium intake on the development and progression of 
CVD. There were largely divergent results between the observational studies and RCTs. 
Earlier retrospective case-control studies showed that blood selenium concentrations of CVD 
patients were lower than those of healthy population, indicating an inverse correlation 8, 9. A 
significant inverse association between selenium status and risk of coronary heart disease was 
reported in a meta-analysis of 25 observational studies 8, yet there has been little research on 
whether there is a threshold effect for the relation between selenium concentrations and CVD 
events. Individual observational studies have shown inconsistent findings and have not fully 
considered the possible nonlinear relationship. Also, influenced by other antioxidants cannot 
be ruled out in observational studies. Well designed and conducted RCTs, as the most reliable 
design strategy, can avoid most of biases inherent in observational studies and help evaluate a 
possible causal relation. However, a few randomized trials have evaluated the effects of 
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selenium on cardiovascular outcomes 10-13 and showed no obvious benefits from selenium for 
CVD. In addition to heterogeneity in intervention periods and selenium formula and dosage, 
these individual trials are limited by statistical power for addressing specific thresholds of 
circulating selenium concentrations for optimal cardiovascular health. Previously, neither of a 
meta-analysis of 6 RCTs 8 for selenium-containing supplements and a meta-analysis of 12 
RCTs for selenium supplements alone 14 showed significant protective effect on 
cardiovascular endpoints. Both the meta-analyses focused on testing the selenium-CVD 
hypothesis but did not specifically address the dose-dependent relation. There is still 
disagreement between observational studies and RCTs, which largely hindered a consistent 
conclusion to be drawn.  
To maximize statistical power and reduce sampling bias from individual studies, we 
conducted a meta-analysis of available prospective data from both observational studies and 
RCTs. Specifically, our study aimed to provide a comprehensive evaluation of the full 
spectrum of variation in baseline selenium concentrations and its dose-response relationship 
with incident CVDs in prospective observational studies, and determine whether any 
differences in selenium biomarkers by selenium supplementation could account for CVD risk 
in RCTs. 
 
Methods 
Data source and searches 
We searched MEDLINE and EMBASE databases for all relevant articles on selenium 
and cardiovascular disease published up to December 15, 2013. We used the search terms 
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including “selenium”, “selenite”, “selenate”, “cardiovascular disease”, “myocardial 
infarction”, “stroke”, “peripheral arterial disease”, “mortality”, “coronary heart disease”, 
“ischemic heart disease”, “sudden cardiac arrest”, “cardiovascular risk”, “hypertension”, 
“cholesterol”, “hypercholesterolemia”, “hyperlipidemia”, “diabetes”, “arteriosclerosis” and 
“hypertriglyceride”. The search was restricted to English-language only and adults.  
We chose the articles based on the following inclusion criteria: 1) original studies (not 
reviews, meeting abstracts, editorials, letters or commentaries); 2) adult human studies; 3) 
prospective study design (eg, prospective cohort, nested case-control, case-cohort) or RCTs; 
4) prospective studies that provided the relative risk estimation between baseline circulating 
or toenail selenium concentration and CVD incidence or mortality; and 5) RCTs with 
selenium-containing supplements (selenium alone or a combination with other vitamins or 
minerals), which provided available data of selenium dose and CVD incidence or mortality 
and/or circulating concentrations of selenium or selenium protein GPx activity. We also 
manually searched bibliographies from recent reviews and retrieved articles for additional 
studies. Finally, a total of 16 articles of prospective observational studies and 16 articles of 
RCTs were included in this meta-analysis. 
Data extraction 
Two investigators (X Zhang and C Liu) independently selected articles and extracted 
the data. Any discrepancies were resolved by consensus. Information extracted from articles 
included population source, study design, follow-up period, sample size, subject 
characteristics (age and sex), selenium biomarkers, CVDs endpoints, selenium forms and 
dose (RCTs). When results were available on different subpopulations in the same cohort 1, 3, 
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10, 15-17 and single RCT 18, 19, we considered each subpopulation as an independent study in the 
meta-analysis (basic study characteristics were described in supplemental table 1 for 
prospective studies and in supplemental table 2 for RCTs).  
Of 16 prospective observational studies, most of them (14) provided RRs or hazard 
ratios and 95% CIs for the relation between baseline selenium concentrations and CVDs 
events. Two articles provided RRs for selenium concentrations as a continuous variable were 
not included in the analysis due to uncertain comparison scales 20, 21. We alternatively 
calculated crude RRs in the studies that only provided exact numbers of events 16, 17 and 
chose RRs estimated from the models fully adjusted for major confounders as main results in 
the articles with several estimation models. 
Statistical analysis 
We analyzed observational studies and RCTs respectively and estimated the pooled RRs 
by DerSimonian and Laird’s random effect model in which each study was weighted by the 
inverse of sum of within-study plus between-study variance 22. Between-study heterogeneity 
was tested by Cochrane’s Q statistic, I2 and H statistics, respectively. The percentages of I2 
around 25% (I2=25), 50% (I2=50), and 75% (I2=75) indicate low, medium, and high 
heterogeneity, respectively. An H statistics <1.2 indicates little heterogeneity and an H >1.5 
raises caution regarding notable heterogeneity. We used Begg’s adjusted rank correlation test 
and Egger’s regression asymmetry test to test publication bias 23, 24. 
For observational studies, we also explored differences of the pooled RRs from baseline 
measurements, including sex (women, men, or mixed), age (<60y and ≥60y), sample size 
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(<1000 and ≥1000), covariance adjustment (BMI and smoking), and CVD endpoints (CVD, 
CHD, MI, and stroke).  
We used the method proposed by Greenland and Longnecker 25 to assess the linear 
relationship of selenium concentrations and CVD risk. To explore a possible non-linear trend, 
we first graphically examined the relation shape by using LOWESS smoothed curve and 
quadratic curve; second, we applied the 2-stage random-effect dose-response meta-analysis 
method proposed by Orsini with 3 fixed knots at percentiles of 10th, 50th, and 90th for the 
distributions of reported circulating selenium concentrations across all included studies 26, 27. 
The concentration values of each category were determined as the median or mean 
concentrations if available; otherwise we calculated the means or midpoints of the lower and 
upper bounds instead. If there was an open lower or upper-bound, it was estimated by one 
known bound minus or plus the other half width of the adjacent category.  
For RCTs, the pooled RRs for the overall effect of selenium supplementation on CVD 
events were calculated. We then examined whether sample size (<1000 and ≥1000), trials 
duration (≤5y and >5y), selenium supplements (selenium alone and a combination of 
selenium with other antioxidants), supplemental dose (≤100μg/day and 200μg/day), and 
selenium formulation (bio-selenium and all others) modified the association. Changes in 
blood selenium concentrations in response to supplementation were derived, respectively, in 
6 trials with ≤100μg/day supplements and 4 trials with 200-300μg/day supplements. We 
calculated the weight mean difference of circulating selenium concentrations comparing the 
treatment to the placebo groups. 
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All analyses were performed using the STATA software (version 13, STATA Corp., 
College Station, Texas). Statistical significance was defined as two-tailed α<0.05. 
 
Results 
A total of 16 prospective studies involving 35 607 participants and 4 421 incident CVD 
cases were included in this meta-analysis (Figure 1). Of them, 11 were cohort studies and 6 
were nested case-control studies. Most studies (13 studies) were population-based and 3 were 
health professional populations 13, 28, 29. Biospecimen tissues for selenium concentrations 
included serum (13 studies), erythrocyte (1 study) 30, plasma (1 study) 29, and toenail (2 
studies) 13, 28. 
Of all 16 trials, 37 572 participants (range: 23 to 17 448; median: 351) took the median 
dose of 100μg/day (range: 75 to 300μg/day) selenium supplements for 2 weeks to 114 
months duration (median: 12 months). 14 of all trials were placebo-controlled double-blinded 
design and 2 used open label design 31, 32. Selenium formulation included L-selenomethionine 
33-35, sodium selenite 36, 37 and selenium-enriched yeast 33, 38. One study did not report form 
information 39. Of all included trials, 9 trials estimated RRs of CVDs mortality or incidence, 
(Supplemental table 2), 10 trials reported information of selenium biomarkers, and only 3 
trials 33, 39, 40 provided both. 
Selenium Concentrations and CVD Events in Prospective Observational Studies  
By combining evidence from 16 studies, the pooled RR for the highest (median: 
101.5μg/L) versus the lowest category (median: 53.7μg/L) of baseline blood 
(serum/plasma/erythrocyte) selenium concentrations was 0.87 (95% CI: 0.76, 0.99), 
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indicating a significant but modest association between baseline selenium concentrations and 
CVD risk (Figure 2). Neither publication bias nor between-study heterogeneity was 
statistically significant. In stratified analyses (Table 1), none of sex, follow-up duration, 
sample size, specimen type, adjustment for BMI or smoking, and baseline selenium 
concentrations seemed to materially modify the inverse association. The inverse associations 
were more evident among those studies with lower median or mean baseline selenium 
concentrations (<106μg/L) (RR, 0.77; 95% CI: 0.61, 0.96) than those with higher (≥106μg/L) 
(RR, 0.93; 95% CI: 0.80, 1.10), but the interaction was not significant (P=0.14). In addition, 
there was no evidence for significant relation between toenail selenium concentrations and 
CVD based on 2 studies (Figure 2).  
The overall dose-response relation was assessed across the range of selenium 
concentrations between 30μg/L and 165μg/L. For each 25μg/L increment in circulating 
selenium concentrations, the pooled RR was estimated to be 0.89 (95% CI: 0.84, 0.95). The 
analysis modeled by restricted cubic spline suggested a reasonably nonlinear relationship 
between circulating selenium and CVD risk (Supplemental Figure 1). The curve showed 
that selenium concentrations were significantly associated with lower risk of CVD at a range 
from 55 to 145μg/L with a nadir at 125μg/L as compared with low selenium concentrations 
(median: 53.7μg/L) (Figure 3). The association was the null when it exceeded 145μg/L. 
Evidence was insufficient to examine the relation between selenium concentration and CVD 
risk when selenium concentration exceeded 150μg/L. 
Selenium Supplementation and CVD Events in RCTs  
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Our meta-analysis of 9 RCTs showed that oral selenium supplements (75- 300μg/day, 
median: 100μg/day) for 6 to 114 months (median: 60 months) did not significantly decrease 
the incidence of CVD events (RR=0.91; 95% CI: 0.74, 1.10) as compared with the placebo 
groups (Table 2). There was a weakly significant between-study heterogeneity (P for 
Cochran Q test=0.07, H statistics=1.4 (1.0, 2.0), and I2 =45 (0, 75)). The Begg’s funnel plot 
showed that the smaller RRs with small standard errors tended to be near the null effect line, 
and larger RRs with large standard errors tended to be under the horizontal line. This 
indicated the presence of publication bias in favor of small trials with positive findings 
(Egger test, P=0.03; Begg’s test P=0.10). In the stratified analyses (Table 2), smaller trials 
with shorter trial durations tended to report positive results; the pooled RR was 0.42 (95% CI, 
0.24, 0.73) for small trials (<1000) with duration ≤ 5 years, and 1.02 (95% CI, 0.93, 1.11) for 
large trials (≥1000) with duration >5 years (P for interaction=0.002). In addition, differences 
in mean ages of participants, study area, selenium formulation, supplemental doses, and CVD 
endpoints did not appear to change the risk of CVD by selenium supplementation. The 
pooled RR was 0.78 (95% CI: 0.49, 1.26) for 6 trials with dose of ≤100μg/day (only one is 
75μg/day 41, 42) and 0.91 (95% CI: 0.69, 1.21) for 3 trials with 200μg/day selenium intake 
(Figure 4).  
Selenium Biomarker Concentrations in Response to Selenium Supplementation 
Our meta-analysis of 10 RCTs showed that oral selenium supplements (median dose: 
200μg/day) for 6.5 months (range: 2 weeks to 144 months) significantly raised blood 
selenium concentrations by 56.4μg/L from a median baseline selenium concentrations of 
98.5μg/L (95% CI for weighted mean differences [WMD]: 40.9, 72.0μg/L). Different 
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formulations of selenium supplements had non-significant effects on the circulating selenium 
concentrations, thus we pooled all trials with different formulations of supplements to address 
following does-response relationship. A steep linear relationship between supplemental 
duration and concentration changes for dose of 100μg/day before 9 month supplementation 
(Supplemental Figure 2). A similar relationship was showed for dose of 200μg/day before 
13 months after supplementation and then a plateau change between 90 and 110μg/L was 
reached. However, there are not enough data to address the plateau for the dose of 100μg/day. 
Since the cardiovascular health by selenium is thought to be through antioxidant 
function of GPx, we have additionally examined available data from 5 RCTs to character a 
time course of percentage changes of GPx activity in blood after selenium supplementation. 
Percentage changes of GPx activity increased abruptly at 1-2 weeks after oral selenium 
supplement and then reached the maximal levels at 12 weeks (Supplemental Figure 3).  
 
Discussion 
Our meta-analysis of prospective observational studies provided some evidence of a 
possible non-linear, most likely U-shaped, relationship between baseline selenium 
concentrations and CVD. Within a narrow range from 55 to 145μg/L, selenium 
concentrations were associated with a significantly lower risk of CVD. We found no evidence 
for significant effect modifications by sex, follow-up duration, sample size, specimen type, 
baseline selenium concentrations, and adjustment for BMI or smoking. Our meta-analysis of 
RCTs showed no evidence for an overall effect of oral selenium supplements on CVD events 
with a 44% elevation of selenium concentrations. Neither selenium formulation nor dose 
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(100μg/day or 200μg/day) modified this effect. In addition, evidence for publication bias 
indicated that smaller RCTs with positive results may largely account for this significant 
effect on CVD by selenium supplementation as previously reported.  
A previous meta-analysis of prospective observational studies reported a similar inverse 
association between CHD and selenium concentrations although the influence of other 
antioxidants cannot be ruled out in observational studies 8. Selenium status may possibly 
affect this relationship 8 and this relation might be discernible only in a population with lower 
selenium concentrations. The narrow selenium range of CVD reduction (55 to 145μg/L) 
reported by our meta-analysis was similar to the range of adequate selenium levels at 60-
140μg/L as previously reported 6. Due to limited data, we only addressed the non-linear 
relation when selenium concentration did not exceed 150μg/L. Further studies for exact 
boundary of this relationship are warranted. 
The non-linear associations might be influenced by many potential factors, such as 
sample size, duration, specimen types, and baseline selenium status. Adjustment for BMI and 
smoking did not change the strength of the associations, although they were potential 
confounders 43, 44. The median level of blood selenium from observational studies included in 
our meta-analysis was 102.8μg/L, which was slightly lower than that in a nationally 
representative sample of the US population from the NHANES 2003-2004 (136.4 ± 
19.9μg/L) 45. The source of biospecimen for assessment may modify this association 45-47. 
However, there was a small number of studies that assayed biospecimen samples other than 
serum. Also, we were unable to exclude the non-linear association that might be caused by 
statistical fluctuation due to relatively low power. In addition, several lines of evidence seem 
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to support the hypothesis of non-linear relationship between selenium and CVD. For instance, 
a randomized controlled pilot trial of 501 old persons with low selenium status found that low 
dose of selenium supplementation had a significant effect on decreasing total and non-HDL 
cholesterol concentrations, while the effect was non-significant for a high dose 
supplementation (300μg/day) 3. Similarly, a 57% higher risk of diabetes was observed in the 
highest quintile of serum selenium (147.0µg/L) compared with the lowest quintile 
(105.9µg/L) in the NHANES III 49. Taken together, it seems reasonable to speculate that high 
selenium concentrations may be related to elevating levels of some intermediate CVD risk 
factors, including dyslipidemia and type 2 diabetes, and may thus diminish the inverse 
association and even lead to possibly increased risk of CVD risk. Nevertheless, few 
prospective studies have specifically assessed this hypothesis.  
Our meta-analysis of RCTs found that oral selenium supplements had no significant 
effect on CVD, which was consistent with previous meta-analyses 8, 14. Publication bias in 
previous RCTs may possibly explain the observed significant results in some individual 
trials. In particular, most large trials with longer durations reported null findings suggested 
that substantial publication bias due to selective publication of small trials with positive 
results is likely.  
The null effect of selenium supplementation on CVD risk was also complicated by the 
significant between-study heterogeneity in selenium dosage, formula, duration, and 
combinations of supplements. Selenium dosage varied across individual RCTs. These 
differences might have contributed to differential results and led to difficulties in estimating 
the true effect of optimal dose of selenium supplements. Our results clearly show that oral 
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selenium supplements, either dose of 100μg/day or 200μg/day, significantly increases 
selenium concentrations and thereby can replete selenium status in human body. It should be 
noted that circulating selenium after 12 weeks of selenium supplementation were 
significantly elevated by at least 50μg/L comparing with placebo and raised by 150μg/L 
above a median baseline concentrations of 100μg/L. The median of circulating selenium 
concentrations was 123.6µg/L with an interquartile range from 113.7 to 134.7µg/L in a 
nationally representative sample of the US general populations aged ≥20 years, a US. 
National survey data of NHANES III (1988-1994) with 7129 participants 50. In the present 
study, the median circulating levels of all 10 included trials were 97µg/L (interquartile range: 
90-108µg/L) at baseline, which were slightly lower than the levels of NHANES III. After 
oral selenium supplementation (with a median dose of 200 mg/day for a median duration of 6 
months), circulating selenium concentrations increased to a median level of 150µg/L 
(interquartile range: 135- 225.7µg/L), which were apparently higher than the estimated levels 
and ranges from NHANES III data. Based on above available evidence, it seems reasonable 
to conclude that significantly elevated selenium concentrations by taking selenium 
supplements at a dose ≥100μg/day were above the range of 55-145μg/L associated with 
significant risk reduction and may not be optimal for CVD health. However, no statistical 
significant of CVD risk was found, although response levels of selenium were significant 
higher, for higher dose of 200mg/day vs. lower dose of 100mg/day. Nevertheless, evidence 
from a dose ≥300μg/day has been limited and inconclusive. Only one RCT reported a 
similarly significant increment of selenium concentrations by 41.2μg/L (29.9-51.3) after a 
higher dose of 300μg/day selenium supplementation for 12 weeks 37. The trial duration might 
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be another potential source of heterogeneity. We observed a significant difference between 
subgroups of duration ≤ 5y and > 5y and a time-dependent change of serum selenium in 
response to supplementation, although such a difference might be caused by chance due to 
small sample sizes in subgroups.    
In addition, available evidence indicates that the role of selenium in human health is 
primarily due to its presence in selenoproteins, including antioxidant enzyme glutathione 
perosidase (GPx), although the exact mechanisms have not yet been fully elucidated. The 
hypothesis of selenium and CVD is supported by the ability of GPx to combat the oxidative 
modification of lipids and to reduce platelet aggregation 5. The findings from our meta-
analysis of GPx activity may explain disparate results between observational studies and 
RCTs for cardiovascular health by selenium. Our meta-analysis of GPx activity showed that 
12-week selenium supplementation caused a maximal increment in GPx activity by 12%. 
However, it remains uncertain whether increment is sustained in the long-term period and 
contributes to the effects of selenium on CVD, due to limited numbers of RCTs with 
available data on GPx activity. 
There is also a concern on the effect of selenium forms of supplements on circulating 
selenium concentrations. Evidence supported that the bio-available of organic selenium is 
superior to that of inorganic selenium because inorganic selenium may increase the oxidant 
stresses 51. Due to limited power, it is difficult to tease out the effect of selenium forms in our 
study. Besides, differences in study population, intervention periods, CVD events, and 
selenium status might have decreased overall statistical power for testing the hypothesis 
whether selenium intake from various supplements exerts any beneficial effect on CVD 
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events.  
Our meta-analysis has several limitations. First, the observational nature of 
prospective studies included in our analysis cannot rule out residual confounding, although 
the consistency of our results across multiple strata and sensitivity analyses minimizes the 
likelihood that residual confounding explains the findings. Second, all included observational 
studies used a single measurement of selenium at baseline, which is not a time-integrated 
measure of selenium status and thereby affect the association. Third, substantial between-
study heterogeneity could influence the accuracy in the pooled estimates. Nevertheless, the 
strength and the direction of the associations were essentially unchanged after excluding the 
studies with extreme values. Fourth, as in any meta-analysis, publication bias is possible, 
although we attempted to retrieve all relevant data. Fifth, the benefits of selenium may only 
present in the deficient population. Due to sparse data, we have insufficient statistical power 
to clearly illustrate this hypothesis. Also we have low power to explore the differential effects 
between selenium supplements alone and combined selenium supplements. Finally, limited 
data from existing prospective studies and RCTs provided insufficient power to detect 
potential sources of heterogeneity and interactions. Additionally, we cannot completely 
exclude the possibility that changes in treatment compliance for all the trials included and 
differential serum selenium concentrations in response to supplementation which may affect 
the explanation for our observed differences between treatment and placebo, especially when 
relevant information was unavailable and trial duration was long. 
Conclusions 
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Our meta-analysis of 16 prospective observational studies suggested a non-linear relation 
between baseline blood selenium concentrations and risk of incident CVDs, the significant 
benefit range of selenium concentration was limited from 55 to 145μg/L. Our meta-analysis 
of 9 RCTs found no overall effect of oral selenium supplements on CVD with significantly 
elevated selenium concentrations at a mean level of approximately 154μg/L, which was 
above the upper limit of the observed beneficial range (145μg/L). Our findings thus indicated 
a need of future long-term RCTs with optimal selenium supplemental dose and safety 
considerations. At presence, available evidence is not conclusive to support the widespread 
use of selenium or selenium-containing supplements for CVD prevention.
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Figure legends 
Figure 1. Flow chart of study selection  
Figure 2. A random-effect meta-analysis of 16 independent prospective studies with adjusted 
relative risk (RR) and 95% confidence interval (CI) of CVDs in relation to blood or toenail 
selenium concentrations (the highest versus the lowest category).  
Figure 3. Dose-response relation between baseline concentrations of selenium and the risk of 
CVDs in 16 independent prospective studies. The relation is fitted by the quadratic regression 
model. Circles indicate RR in each study. The circle size is proportional to the precision of 
the RR (inverse of variance). The grey shaded region shows the 95% CIs around the 
regression line. The selenium concentrations were across the range from 30.5 to 164.6μg/L; 
the median concentrations in all the control groups were 53.7μg/L.  
Figure 4. A random-effect meta-analysis of 9 independent RCTs with adjusted relative risk 
(RR) and 95% CI of CVDs in relation to selenium supplementation (active selenium 
treatment group versus placebo group).  
* Selenium supplemental dose of W C You (2001) was 75μg/day. 
Table 1. Meta-analysis of Prospective Observational Studies that Examined the 
Association between Blood (Serum/Plasma/erythrocyte) Selenium Concentrations and 
CVD Events 
  
No. of 
studies  
Summary of RR 
95% CI  
P for heterogeneity P for 
Interaction Q test H I2 
All studies 14 0.87 (0.76, 0.99) 0.47 1.0 (1.0, 1.5)     5 (0, 57)  
Sex      0.26 
Men  5 0.86 (0.73, 1.01) 0.10 1.4 (1.0, 2.3) 49 (0, 81)  
    Men and Women  9 0.95 (0.89, 1.02) 0.39 1.0 (1.0, 1.7) 6 (0, 67)  
Duration of follow-up      0.15 
< 10 y  8 0.75 (0.58, 0.97) 0.34 1.1 (1.0,1.9)      11 (0, 71)  
≥10 y  6 0.94 (0.81, 1.09) 0.68 1.0 (1.0, 2.0) 0 (0, 75)  
Sample size       0.22 
< 1000 7 0.98 (0.76, 1.28) 0.75 1.0 (1.0, 1.9)      0 (0, 71)  
≥ 1000  7 0.80 (0.65, 0.98) 0.16 1.2 (1.0, 1.9) 35 (0, 73)    
Baseline Selenium Concentrations 
(μg/L) 
     0.14 
< 106 7 0.77 (0.61, 0.96) 0.42 1.0 (1.0, 1.9) 1 (0, 71)      
≥ 106 7 0.93 (0.80, 1.10) 0.49 1.0 (1.0, 1.9) 0 (0, 71)  
Specimen      0.28 
Serum 11 0.83 (0.70, 0.98) 0.31 1.1 (1.0, 1.5) 15 (0, 55)  
Others 3 1.00 (0.60, 1.68) 0.30 1.0 (1.0, 3.1) 0 (0, 90)  
Adjustment for BMI      0.76 
No 11 0.85 (0.72, 1.01) 0.51 1.0 (1.0, 1.6) 0 (0, 60)  
Yes  3 0.80 (0.54, 1.17) 0.13 1.4 (1.0, 2.7) 51 (0, 86)  
Adjustment for smoking      0.38 
No  9 0.91 (0.74, 1.12) 0.74 1.0 (1.0, 1.7) 0 (0, 65)  
Yes  5 0.78 (0.59, 1.03) 0.08 1.4 (1.0, 2.4) 52 (0, 82)  
CVD Endpoints      0.67 
CVD  6 0.88 (0.71, 1.09) 0.39 1.0 (1.0, 2.0) 4 (0, 76)  
CHD  8 0.72 (0.57, 0.92) 0.19 1.2 (1.0, 1.8) 29 (0, 68)  
MI   7 0.81 (0.60, 1.09) 0.75 1.4 (1.0, 2.1) 48 (0, 78)  
Stroke  4 0.69 (0.29, 1.63) 0.003 2.2 (1.3, 3.5)      79 (42, 92)  
 
 
 
Table 2. Meta-Analysis of RCTs that Reported CVD Events for Selenium Supplementation versus 
Placebo groups 
  
No. of 
studies  
Summary of RR 
95% CI  
P for heterogeneity P for 
Interaction 
Q test H I2 
All studies 9 0.91 (0.75, 1.11) 0.07      1.4 (1.0, 2.0) 45 (0, 75)    
Supplements      0.21 
Selenium   3 1.01 (0.83, 1.22) 0.22 1.2 (1.0, 3.8) 33 (0, 93)  
   Combined with other 
antioxidants 
 6 0.74 (0.48, 1.15) 0.075 1.4 (1.0, 2.2) 50 (0, 80)  
Geographical Area      0.16 
USA 5 1.02 (0.92, 1.12) 0.83 1.0 (1.0, 3.1) 0 (0, 90)  
Europe 3 0.63 (0.33, 1.22) 0.02 1.7 (1.1, 2.8)      67 (14, 87)  
Duration of follow-up      0.004† 
≤ 5 y 5 0.49 (0.30, 0.80) 0.36 1.0 (1.0, 2.3) 8 (0, 81)  
> 5 y 4 1.02 (0.93, 1.11) 0.87 1.0 (1.0, 2.6) 0 (0, 85)  
Sample size       0.002† 
< 1000 4 0.42 (0.24, 0.73) 0.37 1.0 (1.0, 2.6) 4 (0, 85)  
≥ 1000 5 1.01 (0.93, 1.11) 0.88 1.0 (1.0, 2.2) 0 (0, 79)  
Duration and sample size       0.002† 
≤ 5 y and < 1000 4 0.42 (0.24, 0.73) 0.37 1.0 (1.0, 2.6) 4 (0, 85)  
> 5 y and ≥ 1000 4 1.02 (0.93, 1.11) 0.87 1.0 (1.0, 2.6) 0 (0, 85)  
Age      0.53 
< 60 y  4 0.93 (0.64, 1.36) 0.28 1.1 (1.0, 2.9)      22 (0, 88)  
≥60 y  5 0.79 (0.55, 1.13)       0.02 1.8 (1.1, 2.8)    67 (15, 87)  
Baseline selenium status      0.19 
≤ 100µg/L  3 0.94 (0.50-1.76) 3.52 1.3 (1.0, 2.4) 43 (0, 83)  
> 100µg/L  2 1.02 (0.93-1.13) 0.004 NA NA  
CVD Events       0.34 
MI  3 0.32 (0.07, 1.64) 0.04 1.8 (1.0, 3.3) 68 (0, 91)  
  CHD 3 1.00 (0.84, 1.21) 0.71 1.0 (1.0, 3.1) 0 (0, 90)  
CVD 5 0.91 (0.72, 1.14) 0.14 1.3 (1.0, 2.2)      42 (0, 79)  
CVD End Points       0.09 
Incidence  4 1.02 (0.93, 1.11) 0.87 1.0 (1.0, 2.6) 0 (0, 85)  
Mortality 7 0.71 (0.47, 1.07) 0.05 1.4 (1.0, 2.2) 52 (0, 79)  
* indicates P<0.05; † indicates P<0.01. 
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Full title: Selenium and Cardiovascular Disease: A Meta-Analysis Assessing the 
Discrepancies between Observational and Randomized Trial Evidence 
Supplemental tables 
Supplemental table 1. Study characteristics of 11 prospective observational studies (16 
independent studies) of blood (plasma/serum/erythrocyte) or toenail Selenium Levels and 
CVDs events 
Supplemental table 2. Study characteristics of 16 RCTs of selenium supplementation and 
CVDs events 
Supplemental figure 
Supplemental Figure 1. Dose-response relation between baseline concentrations of selenium 
and the risk of CVDs in 16 independent prospective studies. The relation is fitted by using the 
restricted cubic spline. 
Supplemental Figure 2. Dose- and Duration-dependent changes of selenium concentrations 
in 10 independent RCTs. Trial data were graphically shown on mean changes in plasma 
selenium concentrations (μg/L) after selenium treatment vs. placebo by two different 
supplemental doses (100 and 200μg/day) from 1 week to 48 months. 
Supplemental Figure 3. Trial data on percentage changes of GPx activity in blood selenium 
levels after selenium treatment compared with baseline from 1 to 48 weeks. The smooth 
curve represents median of percentage changes of GPx activity at baseline, 1, 4, 6, 12, 24 and 
48 weeks.
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Supplemental table 1. Study characteristics of 11 prospective observational studies (16 independent studies) of blood 
(plasma/serum/erythrocyte) or toenail Selenium Levels and CVDs events 
Author, 
Publication year Source Population Design 
Age, 
year 
Follow-u
p years 
N (cases/controls 
or participants, 
gender) 
End Point 
Main Outcome (Highest vs. Lowest) 
Selenium ranges 
(median or mean); RR 
(95% CI)  
Covariates adjusted in the full 
model 
Jukka T. Salonen,  
1982 
Eastern Finland Heart 
Survey, Finland 
Population- 
based 
Cohort 35 - 59 7 
Cases: 208 men and 
75 women; 
Controls: 208 men 
and 75 women 
CVD Mortality 
49.5 vs. 34.5μg/L;  
0.71 (0.2, 2.5) 
History of angina pectoris, congestive 
heart disease and valvular heart defect, 
antihypertensive drug treatment, history 
of MI or AP in either parent, dietary 
saturated fats, intake of strong alcoholic 
beverages, and study area 
Tatu A Miettinen, 
1983 
Eastern Finland Heart 
Survey, Finland 
Population- 
based 
Nested 
Case-control 
study 
48 ± 1 5-7 
Cases: 33 men  
Controls: 64 men 
MI 
93.84 vs. 51.97μg/L;  
0.88 (0.49, 1.57) 
NO 
Jarmo Virtamo, 
1985 
National Death Certificate 
Register, Finland 
Population- 
based 
Cohort 55 - 74 6 
Cases: 141 men 
Controls: 969 men 
Coronary Heart 
Disease 
Mortality 
30.51 vs. 82.29μg/L;  
0.5 (0.25, 1) 
Age and area 
Jukka T. Salonen, 
1985 
Eastern Finland Heart 
Survey, Finland 
Population- 
based  
Cohort 30 - 64  5 
Cases: 69 men and 23 
women 
Control: 69 men and 
23 women 
Coronary Artery 
Disease 
Mortality 
≥45 vs. < 45μg/L;  
1.11 (0.43-3.33) 
Intake of strong alcoholic beverages, 
days of work absenteeism, diabetes, 
history of myocardial infarction or 
angina pectoris in either parent, 
cardiovascular medication and study 
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area 
Jetmund Ringstad, et 
al, 1987 
The Troms Ø Heart Study, 
Norwegian 
Population- 
based 
Nested 
Case-control 
study 
28 - 54 6 
Cases: 59 men 
Controls: 59 men 
Myocardial 
Infarction 
104.64 vs.130.34μg/L;  
1.0 (0.43, 2.5) 
NR 
Frans J Kok, et al, 
1987 
Epidemiologic Prevention 
Study Zoetermeer 
(EPOZ-Study),  
Netherlands 
Population- 
based 
Nested 
Case-control 
study 
37 - 87 9 
Cases: 47 men and 37 
women 
Controls: 94 men and 
74 women 
CVDs Death 
164.6 vs. 141.35μg/L;  
0.5 (0.2, 1.25) 
gender, age, serum cholesterol, systolic 
and diastolic blood pressure, smoking, 
body mass index, week of blood 
collection, years of education, history of 
myocardial infarction, and history of 
stroke. 
P. Suadicani, 1992 
The Copenhagen Male 
Study, Denmark 
Population- 
based 
Cohort 53 - 74 3 
Cases: 107 men  
Controls: 2893 men 
Ischemic Heart 
Disease 
108.22 vs. 64.24μg/L; 0.59 
(0.40, 0.88) 
serum cholesterol, smoking, social class, 
age 
Simonetta Salvini,et 
al,  1995 
The Physicians’ Health 
Randomized Trial Study, 
USA 
Physicians 
Population 
Nested 
Case-control 
study 
40 - 84  5 
Cases: 251 men 
Controls: 251 men 
Myocardial 
Infarction 
136.84 vs. 94.81μg/L; 1.27 
(0.71, 2.29) 
NO 
Jukka Mamiemi, 
1998 
Health survey with 
complete clinical 
evaluation, Finland 
Population- 
based 
Cohort ≥65 13 
Cases: 78 men and 64 
women 
Controls: 104 women 
and 98 women 
CVD death NA; 1.08 (0.68, 1.72) NO 
Wen-Qiang Wei, 
2004 
Nested study from the 
Nutrition Intervention Trial, 
China 
Population- 
based 
Nested 
Case-control 
study 
40 - 69 15 
Cases: 78 men and 38 
women 
Controls: 530 men 
and 457 women 
HD Mortality 
86.79 vs. 52.07μg/L;  
0.66 (0.41, 1.08) 
Sex, age, cholesterol, smoking, drinking, 
and BMI, diastolic 
and systolic blood pressure. 
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N. Tasnime Akbaraly, 
2005 
EVA study, France 
Population- 
based 
Cohort 59 - 71 9 
Cases: 22  
Controls: 1268 
CVD death 
97.4 vs. 76.2μg/L;  
0.82 (0.46, 1.45) 
Sociodemographic characteristics, 
dietary habits, health, and cognitive 
factors. 
Joachim Bleys, et al, 
2008 
The Third National Health 
and Nutrition Examination 
Survey (NHANES III), 
United States 
Population- 
based 
Cohort 20 - 90 12 
Cases: 881 
Control: 13006 
Cardiovascular 
Mortality 
136.92 vs. 110.78μg/L; 1.0 
(0.81, 1.23) 
Age, sex, race/ethnicity, education, 
annual family income, postmenopausal 
status for women, cigarette smoking, 
serum cotinine level, alcohol 
consumption, physical activity, body 
mass index, and vitamin and/or mineral 
supplement use 
Charles B. Eaton et 
al, 2010 
The Third National Health 
and Nutrition Examination 
Survey (NHANES III), 
United States 
Population-bas
ed 
Cohort ≥35 13.4 
Cases: 1038 
Controls: 9493 
CHD Mortality 
133.5 vs. 81μg/L;  
0.87 (0.56, 1.33) 
Age 
Maria Wennberg, 
2011 
Northern Sweden Health 
and Disease Study 
(NSHDS),  Sweden 
Population-bas
ed 
Nested 
Case-control 
study 
30 - 77 13 
Cases: 350 men and 
150 women 
Controls: 350 men 
and 275 women 
Myocardial 
Infarction 
143.4 vs. 108.2μg/L;  
1.0 (0.6, 1.69) 
Apolipoprotein B/ apolipoprotein A-I, 
smoking, systolic blood pressure, 
diabetes, education, consumption of fruit 
and vegetable, wine, strong beer, and 
level of physical activity. 
Kazuko Yoshizawa, 
2003 
Health Professionals 
Follow-up Study (HPFS) , 
USA 
Health 
Professional 
Population 
Nested 
Case-control 
study 
40 - 75 6 
Cases: 470 men 
Controls: 465 men 
Coronary Heart 
Disease 
1.1 vs. 0.71ng/g;  
0.96 (0.63, 1.45) 
Age and smoking   
Swapnil Rajpathak, 
2005 
Health Professionals 
follow-up Study (HPFS), 
USA 
Health 
Professional 
Population 
Nested 
Case-control 
study 
40 - 75 12 
Cases: 202 men 
Controls: 361 men 
CVD  
1.2 vs. 0.76ng/g;  
0.60 (0.36, 0.97) 
Age 
* NA, Not available, NR, Not reported
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Supplemental table 2. Study characteristics of 16 RCTs of selenium supplementation and CVDs events 
First author, 
year 
Source Sample size Age, year Selenium form  
(dose μg/d ) 
Selenium combination Follow-up 
Years 
Quality* End Point 
H. Korpela,1989 Finland 
Acute MI 
Placebo 41 
Treatment: 40 
Placebo: 58  
Treatment: 56  
100μg/day  
Selenium yeast  
No 6m 2 MI and cardiac death, selenium 
concentration 
B. Kuklinski,1994 NR 
Acute MI 
Placebo: 29 
Treatment: 32 
Treatment: 62 
Placebo: 61 
100μg/day 
Bio-selenium 
Coenzyme Q10 12m 1 Death from re-infarction 
B. Greg Brown, 
2001 
HDL-Atherosclerosis Treatment 
Study (HATS) 
Coronary disease patients 
Placebo: 76 
Treatment: 84 
Male: < 63 
Female: < 70 
100μg/day  
NR 
800 IU vitamin E, 1000 mg 
vitamin C, 25 mg natural 
β-carotene 
3y 5 Death from coronary causes, 
nonfatal myocardial infarction, 
stroke, or revascularization for 
worsening ischemia 
W C You 
&Mitchell H. Gail, 
2001 1998 
China  
Village residents 
Male: 1753 
Female: 1658 
35 – 64 75μg/day  
Selenium yeast 
800mg garlic, 4mg garlic oil, 
500mg vitamin C, 200 IU 
vitamin E, 15mg β-carotene 
39m 5 Cardiovascular deaths 
all-cause mortality 
Serge Hercberg, et 
al, 2004 
SU.VI.MAX Study, French 
Volunteers 
Placebo: 6364 
Treatment: 6377 
Female: 35 - 60 
Male: 45 - 60 
100μg/day 
Selenium yeast 
120 mg ascorbic acid, 30 mg 
vitamin E, 6 mg β-carotene, 
and 20 mg zinc 
7.5y 5 Incidence of Ischemic CVD, 
overall mortality, selenium 
concentration 
Mahmoud Zureik, 
2004 
SU.VI.MAX Study, French  
Volunteers 
Placebo: 599 
Control: 563 
≥50 100μg/day  
Selenium yeast 
120 mg vitamin C, 30 mg 
vitamin E, 6 mg beta carotene, 
and 20 mg zinc  
7.2 ± 0.3y 4 CHD incidence  
Saverio Stranges, 
2006 
NPC Trial, USA. 
Population free of CVDs  
Male: 714 
Female: 290 
63.2 200μg/day  
High-selenium baker’s 
yeast tablet 
No 7.6y 5 CVD incidence, CVD mortality, 
all-cause mortality, stroke, MI 
(fatal and nonfatal MI) and CHD 
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Renate Schnabel, 
2008 
SETCAP Study, Germany 
Coronary artery disease patients 
Placebo: 132;  
Se 200: 132;  
Se 500: 128 
66 200 and 500μg/day 
Sodium selenite  
No 12w 5 Selenium concentration 
 
Scott M. Lippman, 
2009 
SELECT, United States, Canada, 
and Puerto Rico 
Volunteers 
Placebo: 8696 
Treatment: 8752 
≥50 200μg/day  
L-selenomethionine  
No 7 -12y 5 Cardiovascular deaths, all-cause 
death and cardiovascular events 
(mortality and incidence), selenium 
Margaret P. 
Rayman, 2011 
PRECISE Pilot Study, United 
Kingdom 
Volunteers 
Placebo: 107 
Se 100: 123 
Se 200:124 
Se 300: 120 
67.4 ± 4.1 100, 200 and 300μg/day  
High-selenium yeast 
No ≥6m. 5 Selenium concentration 
Urban Alehagen, 
2012 
NR 
Rural municipality inhabitants 
Male: 225 
Female: 218 
76.2 200μg/day 
Organic selenium yeast 
Coenzyme Q10 5y 5 CVD and all-cause mortality 
Jody C Miller 
2012 
 
New Zealand 
Patients with coronary artery 
disease 
Male: 138 
Female: 117 
38 – 90 100μg/day  
L-selenomethionine 
No 12w 5 Selenium concentration 
Wayne Chris 
Hawkes 
2008 
North American 
Healthy men 
Male: 42 18 – 45 300μg/day  
High-Se Baker’s yeast 
No 48w 4 Plasma Se 
Gitte Ravn-Haren 
2008 
Denmark 
Healthy male volunteers 
Placebo: 20 
Selenate: 20 
Se-enriched yeast: 20 
Se-enriched milk: 20 
18 – 40 Selenate and Se-enriched 
yeast: 300μg/day   
No 4w 4 Selenium concentration 
P. V. Luoma 
1985 
Finland 
Healthy medical students 
volunteered 
Male: 8 
Female: 15 
21 – 34 Selenium yeast tablets: 
96μg/day 
No 2w 4 Selenium concentration 
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James R. Marshall 
2011 
USA 
High-grade prostatic intraepithelial 
neoplasia patients 
Placebo: 51 
Treatment: 46 
≥40 Selenomethionine 
200μg/day 
No 3y 4 Selenium concentration 
*The 5-point Jadad Score based on the description of randomization, double blinding and withdrawals. NA, not available. NR, not reported 
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Supplemental figure 3. 
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